Trial Profile
Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2016
Price :
$35
*
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SMART
- Sponsors Pharmacyclics
- 15 Mar 2009 Primary endpoint results published in International Journal of Radiation Oncology Biology Physics 73: 1069-1076, No. 4, 15 Mar 2009
- 21 Jul 2006 Status change
- 29 Sep 2005 New trial record.